Healthineers Faces a Margin Test as Olyrian Spinoff and a Softer 2027 Guide Collide

Siemens Healthineers has handed investors two competing narratives in the space of a week: a wave of bullish analyst revisions and a profit outlook that, on paper, points backwards. Barclays raised its price target to EUR 51 from EUR 47.50 on Monday while reaffirming its Overweight rating, and Goldman Sachs lifted its own target to EUR 49 from EUR 43, keeping a Neutral stance. A third research house moved from EUR 50 to EUR 55 the same day and reiterated its buy call. The shares, however, slipped 0.4% in Monday trading after already softening at times on Xetra a day earlier.

The central question for shareholders is whether growth can be converted back into higher earnings. Guidance issued roughly a week ago suggests the opposite in the near term: despite expected revenue gains, the range for adjusted earnings per share sits below the level just achieved.

A base of 2.42 euros, a ceiling of 2.40

For the completed fiscal year, Siemens Healthineers reported adjusted EPS of EUR 2.42. The outlook for the year ahead projects EUR 2.20 to EUR 2.40 — meaning even the top end lands under the result already booked. Comparable revenue growth came in at 4.0% for fiscal 2026, with an adjusted EBIT margin of 16.2%. For fiscal 2027, the company expects comparable revenue growth of 4.0% to 5.0%.

That gap turns profitability into the yardstick. Additional sales would carry more weight with investors if they translated into better earnings, and a push toward the upper end of the company's own range would read more favorably than drift toward the bottom.

Imaging offers the optimistic case

Jefferies analyst Julien Dormois built his Monday assessment on a rebound in the fourth fiscal quarter that came in ahead of expectations. The broker lifted its target to EUR 55 from EUR 50 and confirmed its buy recommendation. The fourth quarter did show more momentum at group level, with comparable revenue growth of 5.9%, according to company figures.

A workable bull case therefore rests on a continued Imaging recovery paired with manageable restructuring costs — and, crucially, on whether that improvement becomes visible in profit rather than revenue alone.

Diagnostics drags, and the separation carries a bill

The counterweight is uneven performance across the portfolio. Even as the group grew, Diagnostics posted a 4.2% decline in the fourth quarter of fiscal 2026, complicating any broad-based earnings recovery.

Siemens Healthineers launched the carve-out of its in-vitro diagnostics business on November 5. The unit is to be built up step by step as a standalone organization under the name Olyrian Diagnostics, with the business established independently by mid-2028. Reuters reported on November 5 that savings of EUR 400 million are planned at Diagnostics, alongside at least EUR 300 million in efficiencies in the core business — measures that will also affect jobs. During the transition, Olyrian remains part of Siemens Healthineers.

Reuters also reported roughly EUR 300 million in cost charges. Finance chief Jochen Schmitz attributed them to the spinoff, the separation from the Siemens group and the refocusing of the ultrasound business. Such burdens could mask operating progress at the group level.

A new name, a February vote, and a February print

Alongside the diagnostics overhaul, the company announced on November 5 that it intends to change its corporate name to Healthineers. The brand transition is scheduled to begin in 2027 and run over three years, subject to shareholder approval at the annual general meeting in February 2027.

The next hard checkpoint comes on February 4, 2027, with first-quarter fiscal 2027 figures. Investors will be watching how revenue growth, operating profitability and restructuring costs interact. If the Imaging rebound holds and the costs of the overhaul stay contained, the softer profit guide can be read as a surmountable phase of strain. Should operating momentum fade or the Diagnostics weakness deepen, the risk of a longer drag on earnings gains weight. The verdict rests less on the announced structure than on its economic consequences — and on whether growth and profit start moving in the same direction again.